Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers

RegulatoryCapricor Duchenne cell therapyRigel Protac medicinePositive

AI Analysis

Summary

Capricor's CEO stated the FDA is willing to review an updated submission for its Duchenne cell therapy. Separately, Cytokinetics has sued Bristol Myers over a heart drug, and Rigel priced the first Protac medicine.

Outcome Details

FDA willing to review updated submission for Capricor's Duchenne cell therapy

Importance:4/10

Sentiment:

0.30

FDA reviewcell therapylitigationProtac medicineregulatory

Related Companies

$BMY

Read the original article

Published by BioPharma Dive on August 14, 2026 1:28 PM

Read Original